Targets › CDH17
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. (UniProt, Q12864)
Open in Phaseline: the race on CDH17, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chimeric Therapeutics | CHM-2101 Cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy | CDH17 | Phase 1 | Neuroendocrine Tumors | Dec 2026 |
| SOTIO Biotech | SOT109 CDH17-directed antibody-drug conjugate with exatecan payload | CDH17 | Phase 1 | Colorectal Cancer (Locally Advanced or Metastatic) | Nov 2027 |
Colorectal Cancer (Locally Advanced or Metastatic) (1) Neuroendocrine Tumors (1)
protein or peptide (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.